Passage Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Passage Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 2.0 times its market value (net cash). Higher than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-8.8×Operating cash was negative last year, while some debt falls due within a year.
Higher than 55% of Healthcare companies in United States.
Cash Cushion Ratio
2.0× cashCash, after subtracting all debt, is 2.0 times its market value (net cash).
Higher than 95% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Passage Bio, Inc. made a loss over the last year. Passage Bio, Inc. owes $0.82 for every $1 it owns. Passage Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPassage Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.53The share price is 2.53 times Passage Bio, Inc.'s book value per share, lower than 51% of Healthcare companies in United States.
Market cap
$11 MThe total market value of all of Passage Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 86% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$4 MWhat Passage Bio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.38Net worth divided by the number of shares. The share price of $3.51 is 2.5 times this, which is the P/B above.
Return on equity (ROE)
-169.1%Passage Bio, Inc. lost 169.1% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
Owes vs Owns
0.82×Passage Bio, Inc. owes $0.82 for every $1 it owns (high), higher than 79% of Healthcare companies in United States.
Dividend yield
NonePassage Bio, Inc. does not currently pay a dividend.
Profit growth
LossPassage Bio, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashPassage Bio, Inc. held $22 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Passage Bio, Inc.: $11 M ÷ $4 M (30 Jun 2026) = 2.5.
What is Passage Bio, Inc.'s return on equity?
Passage Bio, Inc. lost 169.1% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
How much does Passage Bio, Inc. owe compared with what it owns?
Passage Bio, Inc. owes $0.82 for every $1 it owns (high), higher than 79% of Healthcare companies in United States.
Does Passage Bio, Inc. pay a dividend?
No. Passage Bio, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.